BMQ

BMQ: Boston Medical Quarterly was published from 1950-1966 by the Boston University School of Medicine and the Massachusetts Memorial Hospitals. Pages 49-52, v17n2, provided courtesy of Howard Gotlieb Archival Research Center

Truthmakers and modality

This paper attempts to locate, within an actualist ontology, truthmakers for modal truths: truths of the form or . In section 1 I motivate the demand for substantial truthmakers for modal truths. In section 2 I criticise Armstrong’s account of truthmakers for modal truths. In section 3 I examine essentialism and defend an account of what makes essentialist attributions true, but I argue that this does not solve the problem of modal truth in general. In section 4 I discuss, and dismiss, a theistic account of the source of modal truth proposed by Alexander Pruss. In section 5 I offer a means of (dis)solving the problem

BMQ

BMQ: Boston Medical Quarterly was published from 1950-1966 by the Boston University School of Medicine and the Massachusetts Memorial Hospitals

High-efficiency, long-pulse operation of MW-level dual-frequency gyrotron, 84/126GHz, for the TCV Tokamak

The first unit of the dual-frequency gyrotron, 84126GHz/1MW/2s, for the upgrade of the TCV ECH system has been delivered and is presently being commissioned. During a first phase, long-pulse operation (TRF gt 0.5 mathrm{s}) has been achieved and powers in excess of 0.93MW/1.1s and 1MW/1.2s have been measured in the evacuated RF-load at the two frequencies, 84GHz (TE {17,5} mode) and 126GHz (TE {26,7} mode), respectively. Considering the different rf losses in the experimental setup, the power level generated in the gyrotron cavity is in excess of 1.1MW and 1.2MW, with a corresponding electronic efficiency of 35% and 36%. These values are in excellent agreement with the design parameters and would likely lead to a gyrotron total efficiency higher than 50% in case of implementation of a depressed collector. The gyrotron behavior is remarkably reliable and robust with the pulse length extension to 2s presently only limited by external auxiliary systems

Immigration and the Common Profit: Native Cloth Workers, Flemish Exiles, and Royal Policy in Fourteenth-Century London

Drawing on a wide variety of published and unpublished sources, this article reconstructs a crucial episode in the relationship between the English Crown, its native subjects and the kingdom’s immigrant population during the later Middle Ages. Determined that their presence would boost the development of the local textile industries, Edward III encouraged high numbers of skilled Flemish cloth workers who had been exiled from their home county at the start of the 1350s to settle in the realm. Most of them took up residence in London, where they produced higher-quality cloth for the domestic market and, probably, for export. Soon, however, the immigrants’ activities conflicted with the privileges that had structured the capital’s economic life for centuries. Their work was contested by London’s native weavers who, since the middle of the twelfth century, had enjoyed the sole right to produce cloth in the city. Hoping that the control over the immigrants’ activities would help them to overcome the crisis in the market for lower-quality textiles they were struggling with, the natives petitioned the king to obtain the incorporation of the Flemish weavers into their guild for over twenty-five years. Yet, arguing that the Flemings’ contribution benefited the common profit of the whole kingdom in a way that transcended the interests of any particular group, the Crown rejected all their requests and avoided every attempt at discussion. Each time political communication broke down, the native weavers took out their frustrations by physically attacking their Flemish counterparts. These incidents became increasingly violent during the years leading up to the Peasants’ Revolt in 1381 and came to a dramatic conclusion during the rebellion itself

An enactive perspective on comprehending leadership: a comparative case study approach

Leadership is a significant element in the present life of organizations. Recent reviews suggest building novel frameworks through which leadership, as a phenomenon, could be understood comprehensively, considering all the aspects of human experience. The autopoietic perspective on cognition suggests that the quality of human experience is determined by the interplay between the biological and social dynamics of an active situated human agent, we enact our ‘reality’, rather than recognize one. Thus, an integrated approach to the study of any phenomenon in the social domain requires focus on the interrelatedness of the biological, mental and social aspects. This exploratory paper provides an insight into the findings of an empirical study of leadership consonant with an enactive perspective on human experience, including the biological, behavioral and social dynamics of the leadership phenomenon. The research implemented mixed methods under the umbrella of a multidisciplinary comparative case study. Heart rate variability (HRV) demonstrated as the biomarker for physiological data, semi-structured interviews, the Leadership Behavior Development Questionnaire (LBDQ) and a researcher’s reflective diary were used to collect qualitative data and assist in understanding behavioral attributes. The results indicated a correlation between physiology, attitudes and behaviors, social dynamics and performance

Statistical signatures of critical behavior in small systems

The cluster distributions of different systems are examined to search for signatures of a continuous phase transition. In a system known to possess such a phase transition, both sensitive and insensitive signatures are present; while in systems known not to possess such a phase transition, only insensitive signatures are present. It is shown that nuclear multifragmentation results in cluster distributions belonging to the former category, suggesting that the fragments are the result of a continuous phase transition.Comment: 31 pages, two columns with 30 figure

What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines

A number of different malaria vaccine candidates are currently in pre-clinical or clinical development. Even though they vary greatly in their characteristics, it is unlikely that any of them will provide long-lasting sterilizing immunity against the malaria parasite. There is great uncertainty about what the minimal vaccine profile should be before registration is worthwhile; how to allocate resources between different candidates with different profiles; which candidates to consider combining; and what deployment strategies to consider.We use previously published stochastic simulation models, calibrated against extensive epidemiological data, to make quantitative predictions of the population effects of malaria vaccines on malaria transmission, morbidity and mortality. The models are fitted and simulations obtained via volunteer computing. We consider a range of endemic malaria settings with deployment of vaccines via the Expanded program on immunization (EPI), with and without additional booster doses, and also via 5-yearly mass campaigns for a range of coverages. The simulation scenarios account for the dynamic effects of natural and vaccine induced immunity, for treatment of clinical episodes, and for births, ageing and deaths in the cohort. Simulated pre-erythrocytic vaccines have greatest benefits in low endemic settings (<EIR of 10.5) where between 12% and 14% of all deaths are averted when initial efficacy is 50%. In some high transmission scenarios (>EIR of 84) PEV may lead to increased incidence of severe disease in the long term, if efficacy is moderate to low (<70%). Blood stage vaccines (BSV) are most useful in high transmission settings, and are comparable to PEV for low transmission settings. Combinations of PEV and BSV generally perform little better than the best of the contributing components. A minimum half-life of protection of 2–3 years appears to be a precondition for substantial epidemiological effects. Herd immunity effects can be achieved with even moderately effective (>20%) malaria vaccines (either PEV or BSV) when deployed through mass campaigns targeting all age-groups as well as EPI, and especially if combined with highly efficacious transmission-blocking components.We present for the first time a stochastic simulation approach to compare likely effects on morbidity, mortality and transmission of a range of malaria vaccines and vaccine combinations in realistic epidemiological and health systems settings. The results raise several issues for vaccine clinical development, in particular appropriateness of vaccine types for different transmission settings; the need to assess transmission to the vector and duration of protection; and the importance of deployment additional to the EPI, which again may make the issue of number of doses required more critical. To test the validity and robustness of our conclusions there is a need for further modeling (and, of course, field research) using alternative formulations for both natural and vaccine induced immunity. Evaluation of alternative deployment strategies outside EPI needs to consider the operational implications of different approaches to mass vaccination

A High Resolution Study of the HI-H2 Transition across the Perseus Molecular Cloud

To investigate the fundamental principles of H2 formation in a giant molecular cloud (GMC), we derive the HI and H2 surface density (Sigma_HI and Sigma_H2) images of the Perseus molecular cloud on sub-pc scales (~0.4 pc). We use the far-infrared data from the Improved Reprocessing of the IRAS Survey and the V-band extinction image provided by the COMPLETE Survey to estimate the dust column density image of Perseus. In combination with the HI data from the Galactic Arecibo L-band Feed Array HI Survey and an estimate of the local dust-to-gas ratio, we then derive the Sigma_H2 distribution across Perseus. We find a relatively uniform Sigma_HI ~ 6-8 Msun pc^-2 for both dark and star-forming regions, suggesting a minimum HI surface density required to shield H2 against photodissociation. As a result, a remarkably tight and consistent relation is found between Sigma_H2/Sigma_HI and Sigma_HI+Sigma_H2. The transition between the HI- and H2-dominated regions occurs at N(HI)+2N(H2) ~ (8-14) x 10^20 cm^-2. Our findings are consistent with predictions for H2 formation in equilibrium, suggesting that turbulence may not be of primary importance for H2 formation. However, the importance of a warm neutral medium for H2 shielding, an internal radiation field, and the timescale of H2 formation still remain as open questions. We also compare H2 and CO distributions and estimate the fraction of "CO-dark" gas, f_DG ~ 0.3. While significant spatial variations of f_DG are found, we do not find a clear correlation with the mean V-band extinction.Comment: updated to match the final version published in April 201

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

BACKGROUND: Heterologous COVID vaccine priming schedules are immunogenic and effective. This report aims to understand the persistence of immune response to the viral vectored, mRNA and protein-based COVID-19 vaccine platforms used in homologous and heterologous priming combinations, which will inform the choice of vaccine platform in future vaccine development. METHODS: Com-COV2 was a single-blinded trial in which adults ≥50 years, previously immunised with single dose 'ChAd' (ChAdOx1 nCoV-19, AZD1222, Vaxzevria, Astrazeneca) or 'BNT' (BNT162b2, tozinameran, Comirnaty, Pfizer/BioNTech), were randomised 1:1:1 to receive a second dose 8-12 weeks later with either the homologous vaccine, or 'Mod' (mRNA-1273, Spikevax, Moderna) or 'NVX' (NVX-CoV2373, Nuvaxovid, Novavax). Immunological follow-up and the secondary objective of safety monitoring were performed over nine months. Analyses of antibody and cellular assays were performed on an intention-to-treat population without evidence of COVID-19 infection at baseline or for the trial duration. FINDINGS: In April/May 2021, 1072 participants were enrolled at a median of 9.4 weeks after receipt of a single dose of ChAd (N= 540, 45% female) or BNT (N=532, 39% female) as part of the national vaccination programme. In ChAd-primed participants, ChAd/Mod had the highest anti-spike IgG from day 28 through to 6 months, although the heterologous vs homologous geometric mean ratio (GMR) dropped from 9.7 (95%CI: 8.2,11.5) at D28 to 6.2 (95%CI: 5.0, 7.7) at D196. The heterologous/homologous GMR for ChAd/NVX similarly dropped from 3.0 (95%CI:2.5-3.5) to 2.4 (95%CI:1.9-3.0). In BNT-primed participants, decay was similar between heterologous and homologous schedules with BNT/Mod inducing the highest anti-spike IgG for the duration of follow-up. The aGMR for BNT/Mod compared with BNT/BNT increased from 1.36 (95%CI: 1.17, 1.58) at D28 to 1.52 (95%CI: 1.21, 1.90) at D196, whilst for BNT/NVX this aGMR was 0.55 (95%CI: 0.47, 0.64) at day 28 and 0.62 (95%CI: 0.49, 0.78) at day 196. Heterologous ChAd-primed schedules produced and maintained the largest T-cell responses until D196. Immunisation with BNT/NVX generated a qualitatively different antibody response to BNT/BNT, with the total IgG significantly lower than BNT/BNT during all follow-up time points, but similar levels of neutralising antibodies. INTERPRETATION: Heterologous ChAd-primed schedules remain more immunogenic over time in comparison to ChAd/ChAd. BNT-primed schedules with a second dose of either mRNA vaccine also remain more immunogenic over time in comparison to BNT/NVX. The emerging data on mixed schedules using the novel vaccine platforms deployed in the COVID-19 pandemic, suggest that heterologous priming schedules might be considered as a viable option sooner in future pandemics. ISRCTN: 27841311 EudraCT:2021-001275-16 FUNDING: UK Vaccine Task Force (VTF), Coalition for Epidemic Preparedness Innovations (CEPI) and National Institute for Health and Carte Research (NIHR). NVX was supplied for trial use by Novavax, Inc